KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a viru ... s’ natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs. read more